The decision comes at a crucial juncture in the US's vaccination effort, which has gained speed in recent weeks at the same time a worsening outbreak grips the upper Midwest.
President Joe Biden described the approval as an encouraging development in efforts to end the Covid-19 crisis and said this is exciting news for all US citizens.
If J&J's phase 3 trial report very strong efficacy, it will be the single-shot vaccine that can be stored and transported at refrigerator temperatures unlike Pfizer and Moderna.
More than 90% of participants made immune proteins within 29 days after receiving the shot & all participants formed the antibodies within 57 days, according to the report.
The deal comes after a study showed Johnson & Johnson’s candidate vaccine generated strong antibody response in primates and provided protection with a single dose.
J&J announced in June that it had accelerated vaccine trials with ambitions of launching human studies in mid-July. The company will dose its first patients on 22 July in Belgium.
The industry forecasts exports are set to grow 16% in 2025-26, boosted by surplus domestic production and a drive to push into 26 underserved global markets with strong potential.
Taylor ‘Fema’ Hiester, commander of USAF F-16 Viper Demo Team, hit out at air show organisers for continuing with the show after Wing Commander Namansh Syal lost his life in the incident.
It is a brilliant, reasonably priced, and mostly homemade aircraft with a stellar safety record; only two crashes in 24 years since its first flight. But its crash is a moment of introspection.
COMMENTS